Core Insights - Abbott Laboratories (ABT) has received FDA approval for its Volt PFA System to treat atrial fibrillation (AFib), with plans to begin commercial cases in the U.S. and expand in the EU following earlier CE Mark approval [1][4] Company Performance - Following the FDA approval news, ABT shares dipped slightly by 0.2%, but have increased by 9.5% over the past year, outperforming the industry growth of 0.5% [2] - ABT has a market capitalization of $218.16 billion and an earnings yield of 4.1%, significantly higher than the industry's 0.1% [3] Volt PFA System Details - The Volt PFA System was approved based on the VOLT-AF IDE study involving 392 patients across multiple countries, demonstrating safety and effectiveness for both paroxysmal and persistent AFib [4][7] - The system integrates mapping, pacing, and ablation in one catheter, designed to work with Abbott's EnSite X EP System for enhanced cardiac mapping [5][7] Significance of Volt PFA System - The proprietary design of the Volt PFA System allows for efficient energy transfer to targeted tissue, aiming to reduce the need for repeat ablations and complications [6][8] - Patients can undergo the procedure with conscious sedation instead of general anesthesia, which is beneficial for those who may have barriers to anesthesia [8] Industry Context - Nearly 12 million people in the U.S. over the age of 65 have AFib, a number expected to double in the next 20 years, highlighting a growing market for effective treatment options [9] - AFib significantly increases the risk of stroke, making minimally invasive cardiac ablation procedures essential for many patients when other treatments fail [9] Additional Developments - Abbott has expanded its Lingo biowearable continuous glucose monitor system to Android devices, broadening its user base significantly [10]